Paper Review Records
All Paper Review Records
24 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Fluzoparib combined with docetaxel followed by epirubicin and cyclophosphamide as neoadjuvant therapy in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer: a single-arm phase II study
Zhe Wang; Liu Yang; Pu Du; Ge Zhao; Lan Hou; Yuan Qin; Huan Zhang; Zelin Tian; Yike Li; Mingkun Zhang; Juliang ZhangShow moreShow less
1. Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, China; 2. School of Medicine, Northwest University, Xi’an, ChinaShow moreShow less
Association between screen-detected health-related social needs and nonadherence to endocrine therapy in patients with nonmetastatic breast cancer: an observational study
Nadia Liyanage-Don; David DeStephano; Claire Sathe; Shing Lee; Melissa Beauchemin; Melissa Accordino; Dawn Hershman; Ian M. KronishShow moreShow less
1. Department of Medicine, Columbia University Irving Medical Center, New York, USA; 2. Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA; 3. Department of Biostatistics, Columbia University Mailman School of Public Health, New York, USAShow moreShow less
The landscape of cell surface target expression in treatment resistant early-stage breast cancer
Per Karlsson; Marina N. Sharifi; Erik Holmberg; Hamza Bakhtiar; Emma Niméus; Fredrika Killander; Martin Sjöström; Shuang G. ZhaoShow moreShow less
1. Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden; 2. Department of Medicine, University of Wisconsin, Madison, USA; 3. Department of Radiation Medicine, University of Wisconsin, Madison, USA; 4. Institute of Clinical Sciences, Lund University, Lund, Sweden; 5. Department of Surgery, Skåne University Hospital, Malmö, Sweden; 6. Department of Haematology, Oncology, Radiations Physics, Skåne University Hospital, Lund, Sweden; 7. Department of Urology, University of California, San Francisco, USA; 8. University of Texas MD Anderson Cancer Center, Houston, USAShow moreShow less
Chemoendocrine therapy versus tamoxifen with ovarian function suppression in women with node-positive breast cancer
Yung-Huyn Hwang; Sae Byul Lee; Jisun Kim; Il Yong Chung; BeomSeok Ko; Hee Jeong Kim; Jong Won Lee; Byung Ho Son; Tae-Kyung Robyn YooShow moreShow less
1. Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic ofShow moreShow less
Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants
P. V. B. D. Cerqueira; F. A. B. Campos; S. M. Caputo; E. Rouleau; H. K. Mantovani; L. R. da Silva; A. L. Cicilini; S. M. Sanches; F. Makdissi; A. A. B. A. da Costa; M. De Brot; C. Osório; V. Castro Vasconcelos; V. Cordeiro de Lima; J. C. Casali da rocha; D. Carraro; G. Torrezan; E. Santana dos SantosShow moreShow less
1. A.C. Camargo Cancer Center, São Paulo, Brazil; 2. Department of Oncology, Instituto De Assistência Médica Ao Servidor Público Estadual, São Paulo, Brasil; 3. Department of Oncology, Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, Brazil; 4. Department of Genetics, Institut Curie, Paris Sciences Lettre University, Paris, France; 5. Department of Genetics, Gustave Roussy, Paris, France; 6. UNICAMP - Universidade Estadual de Campinas, São Paulo, BrasilShow moreShow less
Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice
Claire E. Smith; Avina Rami; Tianyu Li; Nabihah Tayob; Pooja Patel; Harold J. Burstein; Sandra McAllister; Rachel Abelman; Rachel A. FreedmanShow moreShow less
1. Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; 2. Department of Medicine, Harvard Medical School, Boston, USA; 3. Internal Medicine, Brigham and Women’s Hospital, Boston, USA; 4. Data Sciences, Dana-Farber Cancer Institute, Boston, USA; 5. Hematology Division, Brigham and Women’s Hospital, Boston, USA; 6. Mass General Brigham Cancer Institute, Boston, USAShow moreShow less
FAQ
How long does BREAST CANCER RESEARCH AND TREATMENT take to review a manuscript?
As of 2026-11-19, CrushSCI has 24 complete review records for BREAST CANCER RESEARCH AND TREATMENT. The fastest paper went from submission to acceptance in 11 days (Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice, received 2026-10-02, accepted 2026-10-13); the slowest took 229 days. The average is 114.4 days and the median is 108.5 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
